Динамика ремоделирования левого желудочка у больных артериальной гипертензией с сахарным диабетом 2-го типа и ожирением под влиянием одногодичной комбинированной терапии
| Autor: | O.M. Shenyavska, K.O. Yushko, S.M. Koval, V. Yu. Galchinska, M.Yu. Penkova, I.A. Korneichuk, T. G. Starchenko, O.V. Mysnychenko, O.M. Lytvynova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | HYPERTENSION. :53-59 |
| ISSN: | 2307-1095 2224-1485 |
| Popis: | Background. Pathological left ventricular remodeling in patients with arterial hypertension combined with type 2 diabetes and obesity is associated with a significant increase in cardiovascular risk and requires early and adequate drug correction. Materials and methods. The study included 38 patients with stage 2 hypertension associated with type 2 diabetes and abdominal obesity. The examination was carried out before and after one-year therapy with angiotensin II receptor blocker olmesartan and calcium antagonist lercanidipine in combination with atorvastatin and metformin. Results. Patients showed a high frequency of pathological types of left ventricular remodeling (concentric and eccentric left ventricular hypertrophy — 50 and 37 %, respectively) with the development of left ventricular diastolic dysfunction in 89 % of cases. Combined therapy contributed to a significant decrease in the severity of left ventricular hypertrophy and the frequency of diastolic dysfunction. Conclusions. Long-term use of olmesartan and lercanidipine in combination with atorvastatin and metformin in patients with arterial hypertension associated with type 2 diabetes and abdominal obesity is an effective method of inhibiting the progression of pathological left ventricular remodeling. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|